Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc.

Brown Advisory Inc. reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 33.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,219 shares of the company’s stock after selling 296,323 shares during the period. Brown Advisory Inc.’s holdings in Neurocrine Biosciences were worth $75,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in NBIX. Geneos Wealth Management Inc. raised its holdings in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares in the last quarter. WPG Advisers LLC bought a new position in Neurocrine Biosciences during the 1st quarter valued at $32,000. SVB Wealth LLC acquired a new position in shares of Neurocrine Biosciences during the 1st quarter valued at $35,000. MAI Capital Management raised its stake in shares of Neurocrine Biosciences by 101.2% in the 2nd quarter. MAI Capital Management now owns 328 shares of the company’s stock worth $41,000 after buying an additional 165 shares in the last quarter. Finally, True Wealth Design LLC lifted its holdings in shares of Neurocrine Biosciences by 1,215.4% in the second quarter. True Wealth Design LLC now owns 342 shares of the company’s stock valued at $43,000 after buying an additional 316 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the subject of several research reports. Needham & Company LLC raised their target price on Neurocrine Biosciences from $170.00 to $184.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Royal Bank Of Canada raised their price objective on shares of Neurocrine Biosciences from $156.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. lifted their price objective on shares of Neurocrine Biosciences from $171.00 to $179.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. UBS Group increased their target price on shares of Neurocrine Biosciences from $188.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Finally, Zacks Research upgraded shares of Neurocrine Biosciences from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $172.00.

Neurocrine Biosciences Trading Up 0.8%

NBIX stock opened at $155.51 on Friday. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.67. The firm has a 50-day moving average of $143.72 and a two-hundred day moving average of $135.95. The firm has a market capitalization of $15.51 billion, a PE ratio of 37.20, a P/E/G ratio of 1.01 and a beta of 0.27.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, October 28th. The company reported $2.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.58 by $0.59. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The business had revenue of $794.90 million for the quarter, compared to analyst estimates of $746.61 million. During the same quarter in the previous year, the business earned $1.81 earnings per share. The firm’s revenue was up 27.8% compared to the same quarter last year. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Insider Activity

In other Neurocrine Biosciences news, Director George J. Morrow sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the sale, the director directly owned 7,068 shares in the company, valued at approximately $1,013,339.16. This trade represents a 67.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Kyle Gano sold 300 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $141.97, for a total value of $42,591.00. Following the transaction, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $19,933,581.79. This trade represents a 0.21% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 33,300 shares of company stock worth $4,925,901 over the last quarter. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.